Replimune (REPL) Change in Acquisitions & Divestments (2018 - 2026)
Replimune (REPL) posted Change in Acquisitions & Divestments of $90.5 million for Q1 2026, down 11.11% sequentially from $101.8 million in Q4 2025, and up 39.03% YoY from $65.1 million in Q1 2025.
Analysis
Replimune (REPL) Change in Acquisitions & Divestments (2018 - 2026) Analysis & Trends
Replimune has reported Change in Acquisitions & Divestments for 9 years, with the latest figure at $90.5 million in Q1 2026.
- Quarterly Change in Acquisitions & Divestments rose 39.03% year-over-year to $90.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.0 million (up 1.68% YoY) and the FY2026 annual result came in at $393.0 million, up 1.68% from the prior year.
- Change in Acquisitions & Divestments retreated to $90.5 million in Q1 2026 per REPL's latest filing, from $101.8 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $177.1 million in Q2 2023 and troughed at $60.0 million in Q1 2022.
- A 5-year average of $110.3 million and a median of $105.4 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
- The sharpest annual moves came in 2023 and 2025: Change in Acquisitions & Divestments surged 164.39% in 2023, then tumbled 51.2% in 2025.
- Over 5 years, Change in Acquisitions & Divestments stood at $115.7 million in 2022, then surged by 34.46% to $155.5 million in 2023, then slumped by 40.53% to $92.5 million in 2024, then gained by 10.02% to $101.8 million in 2025, then dropped by 11.11% to $90.5 million in 2026.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $90.5 million, $101.8 million, and $95.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.88 Mn |
| Mar 31, 2026 | 90.46 Mn |
| Dec 31, 2025 | 101.77 Mn |
| Sep 30, 2025 | 95.36 Mn |
| Jun 30, 2025 | 105.37 Mn |
| Mar 31, 2025 | 65.07 Mn |
| Dec 31, 2024 | 92.50 Mn |
| Sep 30, 2024 | 92.00 Mn |
| Jun 30, 2024 | 136.91 Mn |
| Mar 31, 2024 | 133.34 Mn |
| Dec 31, 2023 | 155.54 Mn |
| Sep 30, 2023 | 126.35 Mn |
| Jun 30, 2023 | 177.14 Mn |
| Mar 31, 2023 | 127.00 Mn |
| Dec 31, 2022 | 115.68 Mn |
| Sep 30, 2022 | 133.50 Mn |
| Jun 30, 2022 | 67.00 Mn |
| Mar 31, 2022 | 60.00 Mn |
| Dec 31, 2021 | 68.24 Mn |
| Sep 30, 2021 | 68.50 Mn |